KAN571 / Kancera, Karolinska Institute - LARVOL DELTA

Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies (Market Screener) - "Kancera AB...reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. The results show that KAN571: is effective in eliminating primary human cancer cells implanted in rodents; increases the effect of two established and commonly used drugs: venetoclax and ibrutinib; is effective in killing cancer cells that have acquired resistance to ibrutinib and venetoclax."

Preclinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. (PubMed, Cell Death Dis) - "Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC."

IO biomarker • Journal • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • BCL2 • ROR1

[VIRTUAL] Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung (IASLC-WCLC 2020) - "Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in all 8 SCLC cell lines. Conclusion We have demonstrated that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC."

IO biomarker • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • BCL2 • ROR1